Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2011 Columbia Laboratories, Inc. (Nasdaq: CBRX ... ), today announced the publication of Phase III PROCHIEVE® ... Ultrasound in Obstetrics & Gynecology , the leading peer-reviewed ... & Gynecology. The published results indicate ...
... SAN DIEGO, April 6, 2011 ... a leading global medical technology company, today announced ... of pharmaceutical waste, helping hospitals reduce cost, improve ... (Photo:   http://photos.prnewswire.com/prnh/20110406/LA78173 ) (Logo:   ...
Cached Medicine Technology:Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 2Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 3Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 4Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 5Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 6Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 7Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results 8CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste 2CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste 3
(Date:4/22/2014)... may throw tantrums like toddlers, but their total ... say, a gerbil or fox squirrel, according to ... and birds ranging from orangutans to zebra finches. ... Yale and more than two-dozen other research institutions ... evolution of self-control, defined in the study as ...
(Date:4/22/2014)... LOS ANGELES (April 22, 2014) Cedars-Sinai stroke intervention ... Neurological Disorders and Stroke, part of the National Institutes ... fund a multicenter Phase II clinical trial of an ... will be used in combination with recombinant tissue plasminogen ... to treat ischemic strokes shortly after onset. In laboratory ...
(Date:4/22/2014)... We,ve all waited in line and most of us ... we would like. , For Will Mather, assistant ... of Science,s Integrated Science Curriculum, studying lines, or queues, ... deal with bottlenecks that limit the recycling of proteins. ... an assistant professor, has received attention from the National ...
(Date:4/22/2014)... A new prediction tool can help doctors better identify ... after surgery and therefore prevent the often deadly condition, ... the May issue of Anesthesiology . , Affecting ... (ARDS) is a sudden failure of the lungs caused ... to pneumonia or blood infection. High-risk patients can develop ...
(Date:4/21/2014)... OAK BROOK, Ill. Imaging of the coronary arteries ... of arterial plaque and could have a dramatic impact ... high risk of heart attacks and other cardiovascular events, ... the journal Radiology . , Plaque that forms ... in some cases, rupture, leading to potentially fatal heart ...
Breaking Medicine News(10 mins):Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:Queuing theory helps physicist understand protein recycling 2Health News:New tool helps doctors better predict, prevent deadly respiratory failure 2Health News:CT measures potentially dangerous arterial plaque in diabetic patients 2Health News:CT measures potentially dangerous arterial plaque in diabetic patients 3
... could boost sensitivity, amount of information offered by the ... could some day be injected into the body to ... amount of information provided by the images, according to ... act as "smart tags" that identify specific cells, tissues, ...
... of Survivor Cafe Continues Longstanding ... Community Support By Binson,s, DETROIT, June 18 The fight ... Komen Detroit Race for,the Cure(R) with the participation of 344 participants from ... the Komen Race for the Cure Series has been a celebration,of life, ...
... research awards to states in 2007 created more than ... from those new jobs, and,spurred more than $50 billion ... for NIH Threatens New Health Research, U.S.,Medical Leadership, and ... Institutes,of Health has a legacy of great medical accomplishments, ...
... VW Bus For Fundraising Contest, HERNDON, Va., June ... their hands on legendary rock band The Who,s Magic,Bus ... 1965, signed by Roger,Daltrey and Pete Townshend and specially ... target logo. The competition, in aid of Daltrey,s,charity Teenage ...
... June 21, 2008, New Alternatives,for Children (NAC), a New ... disabilities and/or chronic illnesses, will,hold its 3rd Annual NAC ... 12:00 noon to 3:30 pm rain or shine., ... family members,are expected to participate in the 2008 NAC ...
... June 18 After 25 years, 26 chapters,and more ... the brink of a new era. And, beginning in ... alike can read the latest news,and cutting-edge technologies with ... available, in its entirety, online, offering readers,more opportunities to ...
Cached Medicine News:Health News:'Micromagnets' May One Day Enhance MRI Technology 2Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 2Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 4Health News:Report: NIH and Global Health Research are a Major Boon to All State Economies 2Health News:Report: NIH and Global Health Research are a Major Boon to All State Economies 3Health News:Volkswagen Partners With Legendary Rock Band 'The Who' To Raise Money for Teenage Cancer Trust Charity 2Health News:Volkswagen Partners With Legendary Rock Band 'The Who' To Raise Money for Teenage Cancer Trust Charity 3Health News:2008 NAC Kids Olympics Celebrates the Achievements and Persevering Spirits of Hundreds of Children with Disabilities and Chronic Illnesses on Saturday, June 21, 2008 at Riverbank State Park 2Health News:2008 NAC Kids Olympics Celebrates the Achievements and Persevering Spirits of Hundreds of Children with Disabilities and Chronic Illnesses on Saturday, June 21, 2008 at Riverbank State Park 3Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 2Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 3
... The Foundation® PS knee offers a femoral option ... cam action that engages at 60 degrees of ... motion and allow for 130 degrees of flexion. ... design with prominent lateral flare. The constrained tibial ...
... System is designed to provide the surgeon ... clinical indications. Based on the clinically successful ... P.F.C. SIGMA continues a history of innovation ... to address implant longevity by maximizing femoro-tibial ...
... Knee System's curved-on-curved articulation maintains full inter-changeability. ... for better patient fit. The Maxim ... knee's proven concepts with expanded options to ... Maxim is indicated for use in total ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
Medicine Products: